Pricing
  1. US-listed companies
  2. U.S. Stem Cell, Inc.
  3. Raw

U.S. Stem Cell, Inc.【USRM】

Market cap
$64.15K
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022
NET LOSS-4,697,037-4,016,467-3,143,259-2,253,511-1,641,880-2,070,386-3,481,491-2,160,427--2,890,493-3,287,416-2,857,943
Bad debt (recoveries)166,266166,266166,26628,73238,5995,64016,74062,207--93,241616
Interest and amortization of debt discount122546,970818,404675,650126,436195,967-447,380977,386685,326
Gain (loss) on settlement of accounts payable and accrued interest, net-----------12
Gain (loss) on debt extinguishment--12353,690-126,4575,625-182-151,410-447,494
Related party notes payable issued for services rendered-----59,850--316,800----422,722-750,000
Share-based compensation101010537,6061410,002645,4831-701,939556,556384,380
Accounts receivable4,7602,60721,178104,228-21,778-13,36743,67437,283-5,95640,2903,735
Inventories63,70362,954-62,953-17,40624,81228,14622,851--2,678-5,025587
Accounts payable333858,437434,49010,464469,220426,263-149,52173,195274,268
Accrued expenses577313,601365,525224,188435,390226,673-18,347-6,76818,341
Contract liabilities------------3,000
Net cash used in operating activities-----844,690112,2421602,467--478,886-1,057,939-304,852
Proceeds from sale of common shares636465479,625582,80860,000275,000367,700--275,00085,000
Proceeds from related party advances----13,60615,000-130,000-349,68890,000186,210
Repayments of notes payable444232,956266,047386,347530,178656,468-45,71252,23817,618
Proceeds from convertible note payable---------45,000766,00027,000
Repayments of convertible note payable-----------10,000
Net cash provided by financing activities----1-54,995-1,239,152-543,820-497,4561270,592
Net increase (decrease) in cash and cash equivalents---------18,57020,823-34,260
Interest paid-------1-40,98922,7626,113
Income taxes paid------------
Modified retrospective adoption of ASU 2020-06-----------384,174
Common shares issued-----------48,817
Common shares issued upon conversion of convertible notes and accrued interest----------375,58625,000
Common shares issued as equity kicker for convertible notes payable-----------18,563
Common stock issued in lieu of interest177,901271,110499,767705,710528,915193,946----19,80019,511
Monthly payments on notes payable made on behalf of the Company-------189,909---8,250
Beneficial conversion feature recognized on convertible note---------15,000641,688-